Eric L Garland portrait
  • Associate Director of Integrative Medicine - Supportive Oncology, Huntsman Cancer Institute
  • Associate Dean for Research College of Social Work
  • Director, Center on Mindfulness and Integrative Health Intervention Development (C-MIIND), College Of Social Work
  • Professor, College Of Social Work

Research Summary

The goal of my research program is to translate findings from cognitive and affective neuroscience into interventions that effectively target transdiagnostic mechanisms underpinning substance use disorders, emotion dysregulation, and chronic pain syndromes. My treatment development research is focused on Mindfulness-Oriented Recovery Enhancement, a novel therapy that unites mindfulness training, CBT, and principles from positive psychology into an integrative intervention for addiction.


  • PhD, with distinction, Social Work, University of North Carolina at Chapel Hill. Project: Biopsychosocial assessment of a mindfulness-oriented cognitive intervention for alcohol dependence
  • MSW, Social Work, West Virginia Univesity
  • BA, magna cum laude, Psychology, minors Anthropology & Religious Studies, University of Delaware


Dr. Eric Garland, PhD, LCSW is Presidential Scholar, Associate Dean for Research, and Professor in the University of Utah College of Social Work, Director of the Center on Mindfulness and Integrative Health Intervention Development (C-MIIND), and Associate Director of Integrative Medicine in Supportive Oncology and Survivorship at the Huntsman Cancer Institute. Dr. Garland is the developer of an innovative, multimodal mindfulness-based intervention founded on insights derived from cognitive, affective, and neurobiological science, called Mindfulness-Oriented Recovery Enhancement (MORE). As Principal Investigator or Co-Investigator, he has received nearly $40 million in research grants from a variety of prestigious entities including the National Institutes of Health (NIH), the Department of Defense (DOD), and the Patient Centered Outcomes Research Institute (PCORI) to conduct translational research on biopsychosocial mechanisms implicated in stress and health, including randomized controlled trials of MORE as a treatment for prescription opioid misuse and chronic pain conditions. In recognition of his expertise in mindfulness research, in 2012 Dr. Garland was named Fellow of the Mind and Life Institute, the world’s premier, multidisciplinary organization for the scientific study of contemplative practices. Dr. Garland currently serves as the Chair of the Research Working Group of the national Academic Consortium for Integrative Medicine and Health. Dr. Garland has had over 130 scientific articles and book chapters published in respected, peer-reviewed outlets, and he currently serves as Associate Editor for the journal Mindfulness. To complement his expertise in clinical research, Dr. Garland is a licensed psychotherapist (LCSW) with more than a decade of clinical experience working with persons suffering from addictive behaviors, mood disorders, traumatic stress, chronic pain, and psychosomatic conditions. He has provided mindfulness-based therapy, cognitive-behavioral therapy, and clinical hypnosis for these patients across a wide range of integrative medicine and mental health settings.

Selected Works

  • Garland EL, Bryan CJ, Nakamura Y, Froeliger B & Howard MO (2017). Deficits in autonomic indices of emotion regulation and reward processing associated with prescription opioid use and misuse. Psychopharmacology. Vol. 234, 621-629. Published, 12/01/2017.
  • Garland EL, Baker AK, Larsen P, Riquino MR, Priddy SE, Thomas E, Hanley AW, Galbraith P, Wanner N & Nakamura Y (2018). Randomized Controlled Trial of Brief Mindfulness Training and Hypnotic Suggestion for Acute Pain Relief in the Hospital Setting. Journal of general internal medicine. Vol. 32, 1106-1113. Published, 01/01/2018.
  • Garland, E.L., Froeliger, B., Zeidan, F., Suveg, K., & Howard, M.O. (2013). The downward spiral of chronic pain, prescription opioid misuse, and addiction: Cognitive, affective, and neuropsychopharmacologic pathways. Neuroscience & Biobehavioral Reviews. Accepted, 08/2013.
  • Garland EL, Howard MO, Zubieta JK & Froeliger B (2018). Restructuring Hedonic Dysregulation in Chronic Pain and Prescription Opioid Misuse: Effects of Mindfulness-Oriented Recovery Enhancement on Responsiveness to Drug Cues and Natural Rewards. (pp. 111-112). Vol. 86. Psychotherapy and psychosomatics. Published, 04/01/2018.
  • Garland, E.L. & Howard, M.O. (2014). Opioid attentional bias and cue-elicited craving predict future risk of prescription opioid misuse among chronic pain patients.Drug and Alcohol Dependence, 144, 283-287. Published, 12/2014.
  • Garland EL, Bryan CJ, Finan PH, Thomas EA, Priddy SE, Riquino MR & Howard MO (2017). Pain, hedonic regulation, and opioid misuse: Modulation of momentary experience by Mindfulness-Oriented Recovery Enhancement in opioid-treated chronic pain patients. (pp. S65-S72). Vol. 173 Suppl 1. Drug and alcohol dependence. Published, 09/01/2017.
  • Garland E., Roberts-Lewis A., Tronnier C., Graves R. & Kelley K. (2017). Corrigendum to "Mindfulness-oriented recovery enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial" [Behav. Res. Ther. 77 (2016) 7-16]. Behaviour Research and Therapy. Published, 01/01/2017.